Roberto Pili

  • 11420 Citations
  • 53 h-Index
1987 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Publications

Article

NCCN task force report: Optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy

Hudes, G. R., Carducci, M. A., Choueiri, T. K., Esper, P., Jonasch, E., Kumar, R., Margolin, K. A., Michaelson, M. D., Motzer, R. J., Pili, R., Roethke, S. & Srinivas, S., Mar 24 2011, In : JNCCN Journal of the National Comprehensive Cancer Network. 9, SUPPL. 1, p. S1-S29

Research output: Contribution to journalArticle

43 Scopus citations

Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: An illustration with the Supportive Care Needs Survey and the QLQ-C30

Snyder, C. F., Blackford, A. L., Brahmer, J. R., Carducci, M. A., Pili, R., Stearns, V., Wolff, A. C., Dy, S. M. & Wu, A. W., Aug 1 2010, In : Quality of Life Research. 19, 6, p. 837-845 9 p.

Research output: Contribution to journalArticle

33 Scopus citations

Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cells

Pettazzoni, P., Ciamporcero, E., Medana, C., Pizzimenti, S., Dal Bello, F., Minero, V. G., Toaldo, C., Minelli, R., Uchida, K., Dianzani, M. U., Pili, R. & Barrera, G., Oct 15 2011, In : Free Radical Biology and Medicine. 51, 8, p. 1610-1618 9 p.

Research output: Contribution to journalArticle

24 Scopus citations

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., Garcia-del-Muro, X., Sosman, J. A., Solska, E., Wilding, G., Thompson, J. A., Kim, S. T., Chen, I., Huang, X. & Figlin, R. A., Aug 1 2009, In : Journal of Clinical Oncology. 27, 22, p. 3584-3590 7 p.

Research output: Contribution to journalArticle

1708 Scopus citations

Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors

Scognamiglio, G., De Chiara, A., Parafioriti, A., Armiraglio, E., Fazioli, F., Gallo, M., Aversa, L., Camerlingo, R., Cacciatore, F., Colella, G., Pili, R. & de Nigris, F., Nov 26 2019, In : British Journal of Cancer. 121, 11, p. 979-982 4 p.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations

Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model

Koskimaki, J. E., Karagiannis, E. D., Tang, B. C., Hammers, H., Watkins, D. N., Pili, R. & Popel, A. S., Feb 1 2010, In : BMC Cancer. 10, 29.

Research output: Contribution to journalArticle

33 Scopus citations

Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy

Affronti, H. C., Rowsam, A. M., Pellerite, A. J., Rosario, S. R., Long, M. D., Jacobi, J. J., Bianchi-Smiraglia, A., Boerlin, C. S., Gillard, B. M., Karasik, E., Foster, B. A., Moser, M., Wilton, J. H., Attwood, K., Nikiforov, M. A., Azabdaftari, G., Pili, R., Phillips, J. G., Casero, R. A. & Smiraglia, D. J., Dec 1 2020, In : Nature communications. 11, 1, 52.

Research output: Contribution to journalArticle

Open Access

Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer a secondary analysis of a randomized clinical trial

Armstrong, A. J., Anand, A., Edenbrandt, L., Bondesson, E., Bjartell, A., Widmark, A., Sternberg, C. N., Pili, R., Tuvesson, H., Nordle, Ö., Carducci, M. A. & Morris, M. J., Jul 2018, In : JAMA Oncology. 4, 7, p. 944-951 8 p.

Research output: Contribution to journalArticle

19 Scopus citations

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer

Carducci, M. A., Musib, L., Kies, M. S., Pili, R., Truong, M., Brahmer, J. R., Cole, P., Sullivan, R., Riddle, J., Schmidt, J., Enas, N., Sinha, V., Thornton, D. E. & Herbst, R. S., Sep 1 2006, In : Journal of Clinical Oncology. 24, 25, p. 4092-4099 8 p.

Research output: Contribution to journalArticle

165 Scopus citations

Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma

Sinibaldi, V. J., Elza-Brown, K., Schmidt, J., Eisenberger, M. A., Rosenbaum, E., Denmeade, S. R., Pili, R., Walczak, J., Baker, S. D., Zahurak, M. & Carducci, M. A., Aug 1 2006, In : American Journal of Clinical Oncology: Cancer Clinical Trials. 29, 4, p. 395-398 4 p.

Research output: Contribution to journalArticle

14 Scopus citations

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer

Pili, R., Hag̈gman, M., Stadler, W. M., Gingrich, J. R., Assikis, V. J., Bjor̈k, A., Nordle, O., Forsberg, G., Carducci, M. A. & Armstrong, A. J., Oct 20 2011, In : Journal of Clinical Oncology. 29, 30, p. 4022-4028 7 p.

Research output: Contribution to journalArticle

155 Scopus citations

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)

Monk, P., Liu, G., Stadler, W. M., Geyer, S., Huang, Y., Wright, J., Villalona-Calero, M., Wade, J., Szmulewitz, R., Gupta, S., Mortazavi, A., Dreicer, R., Pili, R., Dawson, N., George, S. & Garcia, J. A., Oct 1 2018, In : Investigational New Drugs. 36, 5, p. 919-926 8 p.

Research output: Contribution to journalArticle

4 Scopus citations

Phase II Study of Imatinib Mesylate in Patients with Prostate Cancer with Evidence of Biochemical Relapse After Definitive Radical Retropubic Prostatectomy or Radiotherapy

Bajaj, G. K., Zhang, Z., Garrett-Mayer, E., Drew, R., Sinibaldi, V., Pili, R., Denmeade, S. R., Carducci, M. A., Eisenberger, M. A. & DeWeese, T. L., Mar 1 2007, In : Urology. 69, 3, p. 526-531 6 p.

Research output: Contribution to journalArticle

34 Scopus citations

Phase II study on the addition of ASA404 (vadimezan; 5,6- dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC

Pili, R., Rosenthal, M. A., Mainwaring, P. N., Van Hazel, G., Srinivas, S., Dreicer, R., Goel, S., Leach, J., Wong, S. & Clingan, P., May 15 2010, In : Clinical Cancer Research. 16, 10, p. 2906-2914 9 p.

Research output: Contribution to journalArticle

47 Scopus citations

Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer

Rathkopf, D., Carducci, M. A., Morris, M. J., Slovin, S. F., Eisenberger, M. A., Pili, R., Denmeade, S. R., Kelsen, M., Curley, T., Halter, M., Collins, C., Fleisher, M., Heller, G., Baker, S. D. & Scher, H. I., 2008, In : Journal of Clinical Oncology. 26, 18, p. 2959-2965 7 p.

Research output: Contribution to journalArticle

21 Scopus citations

Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma

Wentink, M. Q., Verheul, H. M. W., Pal, S. K., George, S., Voortman, J., Danchaivijitr, P., Adelaiye, R., Poslinski, D., Groman, A., Hutson, A. & Pili, R., Feb 2018, In : Clinical Genitourinary Cancer. 16, 1, p. e1-e9

Research output: Contribution to journalArticle

3 Scopus citations

Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors

Siu, L. L., Pili, R., Duran, I., Messersmith, W. A., Chen, E. X., Sullivan, R., MacLean, M., King, S., Brown, S., Reid, G. K., Li, Z., Kalita, A. M., Laille, E. J., Besterman, J. M., Martell, R. E. & Carducci, M. A., Sep 15 2008, In : Journal of Clinical Oncology. 26, 12, p. 1940-1947 8 p.

Research output: Contribution to journalArticle

108 Scopus citations

Phase i study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

Pili, R., Salumbides, B., Zhao, M., Altiok, S., Qian, D., Zwiebel, J., Carducci, M. A. & Rudek, M. A., Jan 3 2012, In : British Journal of Cancer. 106, 1, p. 77-84 8 p.

Research output: Contribution to journalArticle

103 Scopus citations

Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma

Wood, A., George, S., Adra, N., Chintala, S., Damayanti, N. & Pili, R., Aug 1 2020, In : Investigational New Drugs. 38, 4, p. 1108-1116 9 p.

Research output: Contribution to journalArticle

1 Scopus citations

Phase I trials of anti-ENPP3 antibody–drug conjugates in advanced refractory renal cell carcinomas

Thompson, J. A., Motzer, R. J., Molina, A. M., Choueiri, T. K., Heath, E. I., Redman, B. G., Sangha, R. S., Ernst, D. S., Pili, R., Kim, S. K., Reyno, L., Wiseman, A., Trave, F., Anand, B., Morrison, K., Doñate, F. & Kollmannsberger, C. K., Sep 15 2018, In : Clinical Cancer Research. 24, 18, p. 4399-4406 8 p.

Research output: Contribution to journalArticle

9 Scopus citations

Platelets take up the monoclonal antibody bevacizumab

Verheul, H. M. W., Lolkema, M. P. J., Qian, D. Z., Hilkes, Y. H. A., Liapi, E., Akkerman, J. W. N., Pili, R. & Voest, E. E., Sep 15 2007, In : Clinical Cancer Research. 13, 18, p. 5341-5347 7 p.

Research output: Contribution to journalArticle

83 Scopus citations

Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acidin cancer patients

Li, J., Jameson, M. B., Baguley, B. C., Pili, R. & Baker, S. D., Apr 1 2008, In : Clinical Cancer Research. 14, 7, p. 2102-2110 9 p.

Research output: Contribution to journalArticle

22 Scopus citations

Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint

Collins, C., Carducci, M. A., Eisenberger, M. A., Isaacs, J. T., Partin, A. W., Pili, R., Sinibaldi, V. J., Walczak, J. S. & Denmeade, S. R., Sep 2007, In : Cancer Biology and Therapy. 6, 9, p. 1356-1363 8 p.

Research output: Contribution to journalArticle

Open Access
15 Scopus citations

Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma

Pokuri, V. K., Syed, J. R., Yang, Z., Field, E. P., Cyriac, S., Pili, R., Levine, E. G., Azabdaftari, G., Trump, D. L., Guru, K. & George, S., Feb 1 2016, In : Clinical Genitourinary Cancer. 14, 1, p. e59-e65

Research output: Contribution to journalArticle

31 Scopus citations
3 Scopus citations

Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: Association with outcome and predictive nomogram

Keizman, D., Gottfried, M., Ish-Shalom, M., Maimon, N., Peer, A., Neumann, A., Rosenbaum, E., Kovel, S., Pili, R., Sinibaldi, V., Carducci, M. A., Hammers, H., Eisenberger, M. A. & Sella, A., Dec 31 2012, In : Oncologist. 17, 12, p. 1508-1514 7 p.

Research output: Contribution to journalArticle

64 Scopus citations

Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition

Chintala, S., Najrana, T., Toth, K., Cao, S., Durrani, F. A., Pili, R. & Rustum, Y. M., Jul 17 2012, In : BMC Cancer. 12, 293.

Research output: Contribution to journalArticle

38 Scopus citations

Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth

Deng, X., Shao, G., Zhang, H. T., Li, C., Zhang, D., Cheng, L., Elzey, B. D., Pili, R., Ratliff, T. L., Huang, J. & Hu, C. D., Mar 2 2017, In : Oncogene. 36, 9, p. 1223-1231 9 p.

Research output: Contribution to journalArticle

36 Scopus citations

Psychological status, life and social conditions: A study in a population of institutionalized elderly people

Bartoloni, C., Guidi, L., di Giovanni, A. L., Antico, L., Cursi, F., Pili, R., Tricerri, A., Janiri, L., Mannelli, P., Pariante, C., Menini, E., Carbonin, P. & Gambassi, G., May 1993, In : International Journal of Geriatric Psychiatry. 8, 5, p. 419-426 8 p.

Research output: Contribution to journalArticle

1 Scopus citations

Psychological status and immunological parameters of institutionalized aged.

Bartoloni, C., Guidi, L., Antico, L., Pariante, C. M., Di Giovanni, A., Pili, R., Cursi, F., Tricerri, A., Tempesta, E. & Frasca, D., Jan 1 1991, In : Panminerva medica. 33, 3, p. 164-169 6 p.

Research output: Contribution to journalArticle

4 Scopus citations

Psychological status of institutionalized aged: Influences on immune parameters and endocrinological correlates

Bartoloni, C., Guidi, L., Antico, L., Pili, R., Cursi, F., Carbonin, P., Gambassi, G., Rumi, C., Di Giovanni, A., Menichella, G., Menini, E., Doria, D. F. G. & Doria, G., Jan 1 1990, In : International Journal of Neuroscience. 51, 3-4, p. 279-281 3 p.

Research output: Contribution to journalArticle

5 Scopus citations

Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer

Sternberg, C., Armstrong, A., Pili, R., Ng, S., Huddart, R., Agarwal, N., Khvorostenko, D., Lyulko, O., Brize, A., Vogelzang, N., Delva, R., Harza, M., Thanos, A., James, N., Werbrouck, P., Bögemann, M., Hutson, T., Milecki, P., Chowdhury, S., Gallardo, E. & 6 others, Schwartsmann, G., Pouget, J. C., Baton, F., Nederman, T., Tuvesson, H. & Carducci, M., Aug 1 2016, In : Journal of Clinical Oncology. 34, 22, p. 2636-2643 8 p.

Research output: Contribution to journalArticle

44 Scopus citations

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer

Weiss, A., Ding, X., van Beijnum, J. R., Wong, I., Wong, T. J., Berndsen, R. H., Dormond, O., Dallinga, M., Shen, L., Schlingemann, R. O., Pili, R., Ho, C. M., Dyson, P. J., van den Bergh, H., Griffioen, A. W. & Nowak-Sliwinska, P., Jul 20 2015, In : Angiogenesis. 18, 3, p. 233-244 12 p.

Research output: Contribution to journalArticle

64 Scopus citations

Real-Time Multiplex Kinase Phosphorylation Sensors in Living Cells

Damayanti, N. P., Buno, K., Cui, Y., Voytik-Harbin, S. L., Pili, R., Freeman, J. & Irudayaraj, J. M. K., Aug 25 2017, In : ACS Sensors. 2, 8, p. 1225-1230 6 p.

Research output: Contribution to journalArticle

2 Scopus citations

Recent investigations of histone deacetylase inhibitors in renal cell carcinoma

Pili, R., Jun 9 2009, In : Clinical Advances in Hematology and Oncology. 7, 4, p. 252-254 3 p.

Research output: Contribution to journalArticle

2 Scopus citations
22 Scopus citations

Reproducibility of tumor blood flow quantification with15O-water PET

Lodge, M. A., Jacene, H. A., Pili, R. & Wahl, R. L., Oct 1 2008, In : Journal of Nuclear Medicine. 49, 10, p. 1620-1627 8 p.

Research output: Contribution to journalArticle

22 Scopus citations

Resistance to angiogenesis inhibitors in renal cell carcinoma

Tamaskar, I., Dhillon, J. & Pili, R., Feb 1 2011, In : Clinical Advances in Hematology and Oncology. 9, 2, p. 101-110 10 p.

Research output: Contribution to journalArticle

25 Scopus citations

Restriction of dietary protein decreases mTORC1 in tumors and somatic tissues of a tumor-bearing mouse xenograft model

Lamming, D. W., Cummings, N. E., Rastelli, A. L., Gao, F., Cava, E., Bertozzi, B., Spelta, F., Pili, R. & Fontana, L., 2015, In : Oncotarget. 6, 31, p. 31233-31240 8 p.

Research output: Contribution to journalArticle

23 Scopus citations

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: Evidence from a xenograft study

Hammers, H. J., Verheul, H. M., Salumbides, B., Sharma, R., Rudek, M., Jaspers, J., Shah, P., Ellis, L., Shen, L., Paesante, S., Dykema, K., Furge, K., Teh, B. T., Netto, G. & Pili, R., Jun 2010, In : Molecular cancer therapeutics. 9, 6, p. 1525-1535 11 p.

Research output: Contribution to journalArticle

130 Scopus citations

Selenomethionine and methyl selenocysteine: Multiple-dose pharmacokinetics in selenium-replete men

Marshall, J. R., Burk, R. F., Ondracek, R. P., Hill, K. E., Perloff, M., Davis, W., Pili, R., George, S. & Bergan, R., Jan 1 2017, In : Oncotarget. 8, 16, p. 26312-26322 11 p.

Research output: Contribution to journalArticle

10 Scopus citations

Separation and dual detection of prostate cancer cells and protein biomarkers using a microchip device

Huang, W., Chang, C. L., Brault, N. D., Gur, O., Wang, Z., Jalal, S. I., Low, P. S., Ratliff, T. L., Pili, R. & Savran, C. A., Feb 7 2017, In : Lab on a Chip. 17, 3, p. 415-428 14 p.

Research output: Contribution to journalArticle

12 Scopus citations

Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs

Verheul, H. M. W., Qian, D. Z., Carducci, M. A. & Pili, R., Aug 1 2007, In : Cancer Chemotherapy and Pharmacology. 60, 3, p. 329-339 11 p.

Research output: Contribution to journalArticle

18 Scopus citations

Structural variation and fusion detection using targeted sequencing data from circulating cell free DNA

Gawroński, A. R., Lin, Y. Y., McConeghy, B., Lebihan, S., Asghari, H., Koçkan, C., Orabi, B., Adra, N., Pili, R., Collins, C. C., Sahinalp, S. C. & Hach, F., Apr 23 2019, In : Nucleic acids research. 47, 7, e38.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications

Adelaiye, R., Ciamporcero, E., Miles, K. M., Sotomayor, P., Bard, J., Tsompana, M., Conroy, D., Shen, L., Ramakrishnan, S., Ku, S. Y., Orillion, A., Prey, J., Fetterly, G., Buck, M., Chintala, S., Bjarnasone, G. A. & Pili, R., Feb 1 2015, In : Molecular cancer therapeutics. 14, 2, p. 513-522 10 p.

Research output: Contribution to journalArticle

39 Scopus citations

Symptoms, supportive care needs, and function in cancer patients: How are they related?

Snyder, C. F., Garrett-Mayer, E., Brahmer, J. R., Carducci, M. A., Pili, R., Stearns, V., Wolff, A. C., Dy, S. M. & Wu, A. W., Jun 2008, In : Quality of Life Research. 17, 5, p. 665-677 13 p.

Research output: Contribution to journalArticle

41 Scopus citations

Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma

Kato, Y., Yoshimura, K., Shin, T., Verheul, H., Hammers, H., Sanni, T. B., Salumbides, B. C., Van Erp, K., Schulick, R. & Pili, R., Aug 1 2007, In : Clinical Cancer Research. 13, 15, p. 4538-4546 9 p.

Research output: Contribution to journalArticle

66 Scopus citations

TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC)

Bunch, B., Krishnan, N., Greenspan, R. D., Ramakrishnan, S., Attwood, K., Yan, L., Qi, Q., Wang, D., Morrison, C., Omilian, A., Bshara, W., Pili, R., Trump, D. L., Johnson, C. & Woloszynska, A., Sep 2 2019, In : Cell Cycle. 18, 17, p. 2055-2066 12 p.

Research output: Contribution to journalArticle

1 Scopus citations

Targeting tumor angiogenesis with histone deacetylase inhibitors: The hydroxamic acid derivative LBH589

Qian, D. Z., Kato, Y., Shabbeer, S., Wei, Y., Verheul, H. M. W., Salumbides, B., Sanni, T., Atadja, P. & Pili, R., Jan 15 2006, In : Clinical Cancer Research. 12, 2, p. 634-642 9 p.

Research output: Contribution to journalArticle

224 Scopus citations

Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: Therapy with sequential 1-β -D-arabinofuranosylcytosine, mitoxantrone, and bevacizumab

Karp, J. E., Gojo, I., Pili, R., Gocke, C. D., Greer, J., Guo, C., Qian, D., Morris, L., Tidwell, M., Chen, H. & Zwiebel, J., Jun 1 2004, In : Clinical Cancer Research. 10, 11, p. 3577-3585 9 p.

Research output: Contribution to journalArticle

152 Scopus citations